As you can see from the image below the company has a melanoma drug about ready to submit for on approval and they are working with Roche (Genentech) for the marketing. The skin cancer drug helps sustain life and is an oral medication taken. 
Daiichi Sankyo is located in Japan and for the investors in this biotech company it looks to have a positive outcome, again once approved but the trial results for the melanoma drug look good. Colorectal cancer and breast cancer drugs from Plexxikon are in stage one trials. BD
“Plexxikon announced its agreement to co-promote PLX4032 in the U.S. with Genentech, and is planning to begin building its commercial organization and sales force this year. PLX4032 is being co-developed with Roche, and now Genentech, a member of the Roche Group, under a 2006 license and collaboration agreement between Plexxikon and Roche. The companies plan to file for marketing approval with the health authorities in the U.S. and in Europe for PLX4032, and for its companion diagnostic, in 2011.”
Plexxikon, one of the Bay Area’s breakout biotech success stories of the past year, has concluded with a happy ending.
The Berkeley, CA-based cancer drug developer said today it has agreed to be acquired by Japan-based Daiichi Sankyo for $805 million upfront, plus another $130 million in potential milestone payments that could bring the final price tag to $935 million. Since Plexxikon says it has raised about $67 million in capital since its beginning, it will go down as a company that generated more than a 10-fold return on investment.
Plexxikon, Creator of Hot Melanoma Drug, Bought by Daiichi Sankyo for $805M Upfront | Xconomy
0 comments :
Post a Comment